PTC Therapeutics forecasts 2026 product revenue of $700 to $800 million

Reuters

Jan 12

PTC <a href="https://laohu8.com/S/LENZ">Therapeutics</a> forecasts 2026 product revenue of $700 to $800 million

PTC Therapeutics Inc. has released its financial outlook for 2026, projecting total product revenue in the range of $700 to $800 million, which represents a year-over-year growth of 19% to 36%. The company reported unaudited 2025 total product and royalty revenue of approximately $823 million, exceeding its previous guidance. In 2025, product revenue reached around $587.8 million, with Sephience netting approximately $112.1 million since launch. For 2026, PTC anticipates GAAP research and development (R&D) and selling, general, and administrative (SG&A) expenses to be between $775 million and $815 million. On a non-GAAP basis, excluding estimated non-cash, stock-based compensation expense, R&D and SG&A expenses are expected to be $680 million to $720 million. The company also reported a strong cash position of about $1.94 billion as of December 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY60762) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602489765"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602489765\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602489765?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602489765","market":"us","top_or_hot":-1,"title":"PTC Therapeutics forecasts 2026 product revenue of $700 to $800 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> forecasts 2026 product revenue of $700 to $800 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PTCT\">PTC Therapeutics Inc.</a> has released its financial outlook for 2026, projecting total product revenue in the range of $700 to $800 million, which represents a year-over-year growth of 19% to 36%. The company reported unaudited 2025 total product and royalty revenue of approximately $823 million, exceeding its previous guidance. In 2025, product revenue reached around $587.8 million, with Sephience netting approximately $112.1 million since launch. For 2026, PTC anticipates GAAP research and development (R&amp;D) and selling, general, and administrative (SG&amp;A) expenses to be between $775 million and $815 million. On a non-GAAP basis, excluding estimated non-cash, stock-based compensation expense, R&amp;D and SG&amp;A expenses are expected to be $680 million to $720 million. The company also reported a strong cash position of about $1.94 billion as of December 31, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY60762) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PTC Therapeutics forecasts 2026 product revenue of $700 to $800 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPTC Therapeutics forecasts 2026 product revenue of $700 to $800 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> forecasts 2026 product revenue of $700 to $800 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PTCT\">PTC Therapeutics Inc.</a> has released its financial outlook for 2026, projecting total product revenue in the range of $700 to $800 million, which represents a year-over-year growth of 19% to 36%. The company reported unaudited 2025 total product and royalty revenue of approximately $823 million, exceeding its previous guidance. In 2025, product revenue reached around $587.8 million, with Sephience netting approximately $112.1 million since launch. For 2026, PTC anticipates GAAP research and development (R&amp;D) and selling, general, and administrative (SG&amp;A) expenses to be between $775 million and $815 million. On a non-GAAP basis, excluding estimated non-cash, stock-based compensation expense, R&amp;D and SG&amp;A expenses are expected to be $680 million to $720 million. The company also reported a strong cash position of about $1.94 billion as of December 31, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY60762) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6VW52Q:1","article_id":"2602489765","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602489765","pubTimestamp":1768224680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PTC Therapeutics Inc. has released its financial outlook for 2026, projecting total product revenue in the range of $700 to $800 million, which represents a year-over-year growth of 19% to 36%. The company reported unaudited 2025 total product and royalty revenue of approximately $823 million, exceeding its previous guidance. In 2025, product revenue reached around $587.8 million, with Sephience netting approximately $112.1 million since launch. For 2026, PTC anticipates GAAP research and development (R&D) and selling, general, and administrative  expenses to be between $775 million and $815 million. On a non-GAAP basis, excluding estimated non-cash, stock-based compensation expense, R&D and SG&A expenses are expected to be $680 million to $720 million. The company also reported a strong cash position of about $1.94 billion as of December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PTCT":"PTC Therapeutics Inc.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"PTC Therapeutics预测2026年产品收入为700至8亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTCT":0.9},"content_text":"PTC Therapeutics forecasts 2026 product revenue of $700 to $800 million\n    \n\nPTC Therapeutics Inc. has released its financial outlook for 2026, projecting total product revenue in the range of $700 to $800 million, which represents a year-over-year growth of 19% to 36%. The company reported unaudited 2025 total product and royalty revenue of approximately $823 million, exceeding its previous guidance. In 2025, product revenue reached around $587.8 million, with Sephience netting approximately $112.1 million since launch. For 2026, PTC anticipates GAAP research and development (R&D) and selling, general, and administrative (SG&A) expenses to be between $775 million and $815 million. On a non-GAAP basis, excluding estimated non-cash, stock-based compensation expense, R&D and SG&A expenses are expected to be $680 million to $720 million. The company also reported a strong cash position of about $1.94 billion as of December 31, 2025.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY60762) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}